Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical interleukin-2 for superficial bladder cancer
2004-002821-30Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aldesleukin in bladder cancer, sponsored by National Cancer Institute. Primary endpoint: Recurrence-free survival. Started Oct 2004; status: terminated.
02
Drugs
aldesleukin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2004-002821-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002821-30.